Formosa Pharmaceuticals and Cipla Limited have entered into an exclusive licensing agreement for the commercialization of ...

Under this agreement, Cipla has exclusive rights to market the innovative treatment for post-operative inflammation and pain ...

Brokerage Axis Direct picked five stocks that can generate profits in 0 to 15 days. These are SBI Cards and two more. Check ...

Stay informed with the Cipla Stock Liveblog, your comprehensive resource for real-time updates and in-depth analysis of a leading stock. Get the latest details on Cipla, including: Last traded price ...

Under this agreement, Cipla has exclusive rights to market the innovative treatment for post-operative inflammation and pain ...

This new steroid represents a significant advancement in the ophthalmic market, extending notable patient benefits, the company stated.

An analyst from Master Capital said that Prices of Vedanta have exhibited strong bullish momentum, confirming a breakout ...

An analyst from Axis Securities said that Dr Reddy's Labs has shown signs of weakness following the formation of a double top ...

An index of Indian pharmaceutical company shares slid 2% to its lowest ... January 28, 2025 India's Cipla beats Q3 profit view as strong domestic demand offset weak US sales Cipla , one of ...

Cipla Limited is an Indian multinational pharmaceutical company that is headquartered in Mumbai, Maharashtra. The company is primarily known for producing generic drugs for various therapeutic uses.

This partnership aims to enhance ophthalmic care by providing better treatment for post-operative inflammation and pain in patients across 11 countries. APP13007 is a novel, patent protected and ...

Cipla's ophthalmology division is focused on developing therapies and technologies for glaucoma, dry eye disease, ocular infections and retinal diseases. The strategic licensing agreement with Formosa ...